Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636281 | 1.00 | PRKCI (0.55) | PRKCICYP2A6CA1CA2PIK3CB | |
| SCHEMBL16633327 | 0.88 | PRKCI (0.55) | PRKCICYP2A6PIK3CBHSD11B1MAOB | |
| SCHEMBL593671 | 0.84 | CYP2A6 (0.50) | PRKCICYP2A6CA1CA2PIK3CB | |
| SCHEMBL31326584 | 0.84 | CYP2A6 (0.50) | PRKCICYP2A6CA1CA2PIK3CB | |
| SCHEMBL3965798 | 0.78 | TUBB4A (0.44) | CA1CA2TUBB4ATUBBTUBA3C | |
| SCHEMBL29952406 | 0.78 | TUBB4A (0.44) | CA1CA2TUBB4ATUBBTUBA3C | |
| SCHEMBL2627966 | 0.77 | CA2 (0.39) | PRKCICYP2A6CA1CA2 | |
| SCHEMBL1400341 | 0.75 | PRKCI (0.59) | PRKCICYP2A6PIK3CBHSD11B1MAOB | |
| SCHEMBL29874172 | 0.75 | PRKCI (0.59) | PRKCICYP2A6PIK3CBHSD11B1MAOB | |
| SCHEMBL2693281 | 0.74 | PRKCI (0.41) | PRKCICYP2A6PIK3CBHSD11B1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192215-A | Suzuki coupling method of B (9, 10) o-dibromo-substituted m-carborane and application thereof | 华东理工大学 | 2024-12-27 | — | — | CN | claimed |
| US-11495769-B2 | Inorganic light emitting diode and inorganic light emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| US-20210167321-A1 | INORGANIC LIGHT EMITTING DIODE AND INORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2021-06-03 | — | — | US | claimed |
| EP-3568399-B1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4650002-A1 | ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) | Ludwig-Maximilians-Universität (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12448392-B2 | Spiropiperidine derivatives | CEPHALON LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| WO-2005040131-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | AKZO NOBEL N.V. (NL) | 2005-05-06 | — | — | WO | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004101559-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | PRKCI 1529/4885CYP2A6 555/4885CA1 2762/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | PRKCI 3008/4885CYP2A6 3813/4885CA1 4253/4885 |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | PRKCI 4541/4885CYP2A6 1640/4885CA1 1176/4885 |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | HRH4, HRH3, HRH2 | PRKCI 3159/4885CYP2A6 2266/4885CA1 2197/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | PRKCI 4004/4885CYP2A6 1259/4885CA1 4723/4885 |
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | PRKCI 2326/4885CYP2A6 391/4885CA1 993/4885 |
| US-12448392-B2 | Spiropiperidine derivatives | FASN, FADS2, SCD5 | PRKCI 2051/4885CYP2A6 139/4885CA1 3994/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | PRKCI 1408/4885CYP2A6 318/4885CA1 2331/4885 |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | PRKCI 4541/4885CYP2A6 1640/4885CA1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.